Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme Q10, alpha-lipoic acid, and acetyl-L-carnitine to prevent anti-tuberculosis drug-induced hepatotoxicity
IRCT20150721023282N11Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of coenzyme q10, alpha-lipoic acid and acetyl-l-carnitine in Drug-induced hepatitis (DILI), sponsored by Isfahan University of Medical Sciences. Started Apr 2017; status: completed.
02
Drugs
coenzyme q10alpha-lipoic acidacetyl-l-carnitine
03
Conditions
Drug-induced hepatitis (DILI)
Beyond the preview
Go deeper on IRCT20150721023282N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150721023282N11.